Dr Sophia Moldavsky, MD | |
830 Old Lancaster Rd Ste 206, Bryn Mawr, PA 19010-3118 | |
(610) 525-8110 | |
Not Available |
Full Name | Dr Sophia Moldavsky |
---|---|
Gender | Female |
Speciality | Nephrology |
Experience | 25 Years |
Location | 830 Old Lancaster Rd Ste 206, Bryn Mawr, Pennsylvania |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043234438 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RN0300X | Internal Medicine - Nephrology | MD418591 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Renal Care Group East, Inc. | Bryn mawr, PA | Dialysis facility |
Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
Main Line Hospital Lankenau | Wynnewood, PA | Hospital |
Paoli Hospital | Paoli, PA | Hospital |
Riddle Memorial Hospital | Media, PA | Hospital |
Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Bryn Mawr Medical Specialists Association | 4183610934 | 94 |
News Archive
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.
A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 5 days ago
Entity Name | Bryn Mawr Medical Specialists Association |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1841226099 PECOS PAC ID: 4183610934 Enrollment ID: O20040426000467 |
News Archive
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.
A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 5 days ago
Entity Name | Bryn Mawr Nephrology Assoc Ltd |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093826547 PECOS PAC ID: 6709865751 Enrollment ID: O20040714001338 |
News Archive
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.
A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sophia Moldavsky, MD 830 Old Lancaster Rd Ste 206, Bryn Mawr, PA 19010-3118 Ph: (610) 525-8110 | Dr Sophia Moldavsky, MD 830 Old Lancaster Rd Ste 206, Bryn Mawr, PA 19010-3118 Ph: (610) 525-8110 |
News Archive
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.
A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 5 days ago
Dr. Sameer Gupta, MD, MPH Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010 Phone: 610-527-3800 Fax: 610-527-0334 | |
Kellie Ann Matson, PA-C Nephrology Medicare: Medicare Enrolled Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: 484-337-3000 | |
John Steers, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010 Phone: 610-527-1165 Fax: 610-527-6611 | |
Dr. Clarke U. Piatt, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010 Phone: 610-527-3800 Fax: 610-527-0334 | |
Francis P. Day, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010 Phone: 610-527-3800 Fax: 610-527-0334 | |
Robert R Atkins, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010 Phone: 610-527-3800 Fax: 610-527-0334 |